Healthcare Professionals

Committed to helping you meet the evolving challenges and opportunities in patient care.

Healthcare Professionals
  • Primary Care

    Supporting every aspect of your clinical practice, including physical exam, diagnostic cardiology, vitals monitoring and vision screening

  • Hospital Care

    Advancing products and technologies designed to speed patient recovery and streamline clinical workflows

  • Surgical Care

    Delivering innovations that enable reduced operating times, faster patient recovery and improved outcomes

  • Kidney Care

    Pioneering care in hemodialysis (HD), peritoneal dialysis (PD) and digital health to support better outcomes for your patients

  • Nutritional Care

    Personalizing nutritional care designed to improve patients’ health in the hospital, the ICU and at home

  • Respiratory Care

    Helping your patients with respiratory therapies designed to simplify delivery and improve mobility

  • Our Products

    Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

Perspectives

For nearly a century, we have worked at the intersection of saving and sustaining lives.

Perspectives

Our Story

Our 90-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our Story
  • Our Leadership

    Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere.

  • Our Governance

    We are proud of our strong commitment to maintaining the highest standards of corporate governance.

  • Fueling Collaborative Innovation

    Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

  • Corporate Responsibility

    We strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.

  • Diversity, Equity & Inclusion

    We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

  • Our History

    For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Patients

Helping you reach a healthy life, full of possibility.

Patients
  • General Healthcare

    Whether you are receiving care in the hospital, at your doctor’s office or at home, we are here to support every step of your journey.

  • Nutritional Care

    When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain your nutritional status.

  • Kidney Care

    Kidney disease is an ongoing journey for you and your family. While every journey is unique, Baxter is committed to supporting access to care options to meet your medical and lifestyle needs.

  • Respiratory Care

    We are committed to helping you with innovative products that deliver effective, proven respiratory therapy in the hospital and at home.

Doxil (doxorubicin HCl liposome injection) for Hospital Care

Doxil (doxorubicin HCl liposome injection) for Hospital Care

Vials of Doxil

Doxil  (doxorubicin HCl liposome injection) is indicated for treatment of ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s Sarcoma, and multiple myeloma.

Please read the full Indication(s) and Important Risk Information, including the Boxed Warning in the full prescribing information.

Ovarian Cancer

Doxil is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

AIDS-Related Kaposi’s Sarcoma

Doxil is indicated for the treatment of AIDS-related Kaposi’s Sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

Multiple Myeloma

Doxil, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

Product Details

Doxil uses Stealth liposomes to deliver doxorubicin HCl.1 Stealth technology is a liposomal coating that evades detection and destruction by the immune system.2-3 Encapsulation in Stealth liposomes enables protection of the active drug (doxorubicin HCl) to enhance the chance of reaching the tumor. However, Doxil may also affect normal tissue.2,3 

  • Doxil is a form of doxorubicin HCl encapsulated in stealth liposomes for intravenous use.1
  • Stealth allows Doxil to evade detection and destruction by the immune system, which increases the likelihood of reaching the tumor.4
  • Doxil has a greater chance to reach the tumor tissue, where the medication is released. 

    Prescribing Information

    DOXIL (doxorubicin hydrochloride liposome injection) >

     

    Indications

    DOXIL liposomal infusion is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy.

    DOXIL liposomal infusion is indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.

    DOXIL liposomal infusion, in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy.

    Important Risk Information

    WARNING: CARDIOMYOPATHY and INFUSION-RELATED REACTIONS

    DOXIL liposomal infusion can cause myocardial damage, including acute left ventricular failure.  The risk of cardiomyopathy was 11% when the cumulative anthracycline dose was between 450 mg/m2 to 550 mg/m2. Assess left ventricular cardiac function prior to initiation of DOXIL liposomal infusion and during and after treatment. See additional information on Cardiomyopathy in Warnings and Precautions below.                                   

    Serious, life-threatening, and fatal infusion-related reactions can occur with DOXIL liposomal infusion. Acute infusion-related reactions occurred in 11% of patients with solid tumors. Withhold DOXIL     liposomal infusion for infusion-related reactions and resume at a reduced rate. Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions. See additional information on Cardiomyopathy in Warnings and Precautions below.

    Dosage and Administration - Important Use Information

    Do not substitute DOXIL liposomal infusion for other doxorubicin hydrochloride products.

    Do not administer as an undiluted suspension or as an intravenous bolus.

    Contraindications

    DOXIL liposomal infusion is contraindicated in patients who have a history of severe hypersensitivity reactions, including anaphylaxis, to doxorubicin hydrochloride.

    Warnings and Precautions

    Cardiomyopathy: Doxorubicin hydrochloride can cause myocardial damage, including acute left ventricular failure. The risk of cardiomyopathy with doxorubicin hydrochloride is generally proportional to the cumulative exposure. Administer DOXIL liposomal infusion to patients with a history of cardiovascular disease only when the potential benefit of treatment outweighs the risk.

    Infusion-Related Reactions: Serious, life-threatening, and fatal infusion-related reactions characterized by one or more of the following symptoms can occur with DOXIL liposomal infusion: flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea, and hypotension. 

    Ensure that medications to treat infusion-related reactions and cardiopulmonary resuscitative equipment are available for immediate use prior to initiation of DOXIL liposomal infusion.

    Discontinue DOXIL liposomal infusion for serious or life-threatening infusion-related reactions.

    Hand-Foot Syndrome (HFS) may occur.

    • HFS was generally observed after 2 or 3 cycles of treatment but may occur earlier.
    • Delay DOXIL liposomal infusion for the first episode of Grade 2 or greater HFS
    • Dose Modification or discontinue DOXIL liposomal infusion if HFS is severe and debilitating

    Secondary Oral Neoplasms: Secondary oral cancers, primarily squamous cell carcinoma, have been reported from post‑marketing experience in patients with long-term (more than one year) exposure to DOXIL liposomal infusion. These malignancies were diagnosed both during treatment with DOXIL liposomal infusion and up to 6 years after the last dose. Examine patients at regular intervals for the presence of oral ulceration or with any oral discomfort that may be indicative of secondary oral cancer.

    Embryo-Fetal Toxicity: Based on animal data, DOXIL liposomal infusion can cause fetal harm when administered to a pregnant woman; avoid the use of DOXIL liposomal infusion during the 1st trimester.  Advise pregnant women of the potential risk to a fetus.

    Females and males of reproductive potential to use effective contraception during and for 6 months after treatment with DOXIL liposomal infusion.

    Use in Specific Populations

    Lactation: because of the potential for serious adverse reactions in breastfed infants from DOXIL liposomal infusion, discontinue breastfeeding during treatment with DOXIL liposomal infusion.

    Adverse Reactions

    Most common adverse reactions (>20%) are asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-foot syndrome, rash, neutropenia, thrombocytopenia, and anemia.